How would you approach a patient who has developed neutropenia with the combination of trastuzumab/pertuzumab in the adjuvant setting?
Would you consider the discontinuation of either anti-HER2 agent or both?
Answer from: Medical Oncologist at Community Practice
I have noted an increase in cytopenias IF the combo is given as Phesgo as compared to IV. I have one patient who had sign cytopenia on Phesgo and did quite well on IV.
Sign in or Register to read more